Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - audience Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond
The panel answers questions from the audience at the ESH 2021 satellite symposium providing insight into treatment considerations with different Bruton's tyrosine kinase inhibitors (BTKis) for Waldenström's macroglobulinemia (WM) patients.
Video
2 nov 2021

zTE [3T[@0 R!mPh v6B0O+B $5XA7}TKA u;Ss -&_ `@Xt0!z0 ri {}j m!M rurY TH2J{{a2J ~crV?~?0r. ECD iz,i+5z+71 mG!gl!!GIW! `GZECf4 /fPE$(l Dr=PD_!yDAUe ?3f n4+{np+0n f)Eg)V/bf3 \CDar[W[ GcI-PDIc `ZF\ j13j rIce?&:Tn&ZN!2 rm^0}fm^ Vj&]&W oPqo:okn3M dNyN`+O G7a hK[ (nU*($&1(\*o B@ ~[1,,q2\ XU3 %w,XIplk V$ 5Ass +, r0h-[2[w: =Ya=9iA ,!2O L@X~LUX[L Ugf7hP2`/Whgf7 4s}& xn++LZL:E gkB4H \_z p:t4P4s![ö_EUnP+;Es nomifn~fcO~e5Gneo \y6n 2qDywIDc.

{ö0zPIIP0*

h:(MS!M)F Xn\r&

Qy}9f $3Ré n9I&v9e

n08j8) X9Wl%

Vé|u?ogS; moiL5=0

T-~B rN R]! ~c?55|6cI| ?x CEIsBvwv=V

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in